EA200200643A1 - PYRIDO [2,3-d] PYRIMIDIN-2,7-DIAMINE KINAZ INHIBITORS - Google Patents

PYRIDO [2,3-d] PYRIMIDIN-2,7-DIAMINE KINAZ INHIBITORS

Info

Publication number
EA200200643A1
EA200200643A1 EA200200643A EA200200643A EA200200643A1 EA 200200643 A1 EA200200643 A1 EA 200200643A1 EA 200200643 A EA200200643 A EA 200200643A EA 200200643 A EA200200643 A EA 200200643A EA 200200643 A1 EA200200643 A1 EA 200200643A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted lower
nrr
cor
compounds
porr
Prior art date
Application number
EA200200643A
Other languages
Russian (ru)
Inventor
Ричард Джон Бут
Эллен Майра Добрусин
Вэйра Прэйсэд Венкэйта Нэйджендра Джосьюла
Деннис Джозеф Макнэймара
Питер Лоуренс Тугуд
Original Assignee
Уорнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорнер-Ламберт Компани filed Critical Уорнер-Ламберт Компани
Publication of EA200200643A1 publication Critical patent/EA200200643A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Раскрыты соединения формулы (I), где R, R, R, Rи Rпредставляют собой независимо водород или (не)замещенный низший алкил, (не)замещенный низший алкенил, (не)замещенный низший алкинил или (не)замещенный -(CH)R; Rпредставляет собой галоген, циано, нитро, -R, -NRRили -OR; Rпредставляет собой галоген, циано, нитро, -R, -NRR, -OR, -COR, -COR, -CONRR, -NRCOR, (не)замещенный низший алкенил или (не)замещенный низший алкинил; Rпредставляет собой -COR, -COR, -CONRR, -CSNRR, -C(NR)NRR, -SOR, -SOR, -SONRR, -PORR, PORR, -PO(NRR); Rи Rпредставляют собой независимо водород или (не)замещенный низший алкил; Rпредставляет собой гетероарильную или гетероциклическую группу; Rпредставляет собой циклоалкильную, гетероциклическую, арильную или гетероарильную группу; и n равно 0, 1, 2 или 3. Эти соединения и их фармацевтические композиции пригодны для лечения клеточных пролиферативных нарушений, таких как рак и рестеноз. Эти соединения являются сильными ингибиторами cdks и опосредованных фактором роста киназ.Международная заявка была опубликована вместе с отчетом о международном поиске.Compounds of formula (I) are disclosed, wherein R, R, R, R and R are independently hydrogen or (un) substituted lower alkyl, (un) substituted lower alkenyl, (un) substituted lower alkynyl, or (un) substituted - (CH) R ; R1 is halogen, cyano, nitro, -R, -NRR or -OR; R4 is halogen, cyano, nitro, -R, -NRR, -OR, -COR, -COR, -CONRR, -NRCOR, (un) substituted lower alkenyl or (un) substituted lower alkynyl; Is a -COR, -COR, -CONRR, -CSNRR, -C (NR) NRR, -SOR, -SOR, -SONRR, -PORR, PORR, -PO (NRR); R 4 and R 10 are independently hydrogen or (un) substituted lower alkyl; R4 is a heteroaryl or heterocyclic group; R5 is a cycloalkyl, heterocyclic, aryl or heteroaryl group; and n is 0, 1, 2, or 3. These compounds and their pharmaceutical compositions are suitable for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent cdks inhibitors and kinase growth factor mediated. The international application was published along with an international search report.

EA200200643A 2000-01-25 2001-01-23 PYRIDO [2,3-d] PYRIMIDIN-2,7-DIAMINE KINAZ INHIBITORS EA200200643A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (en) 2000-01-25 2001-01-23 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
EA200200643A1 true EA200200643A1 (en) 2002-12-26

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200643A EA200200643A1 (en) 2000-01-25 2001-01-23 PYRIDO [2,3-d] PYRIMIDIN-2,7-DIAMINE KINAZ INHIBITORS

Country Status (34)

Country Link
EP (1) EP1254137A1 (en)
JP (1) JP4047010B2 (en)
KR (1) KR20020065939A (en)
CN (1) CN1395578A (en)
AP (1) AP2002002586A0 (en)
AR (1) AR030044A1 (en)
AU (1) AU2542501A (en)
BG (1) BG106850A (en)
BR (1) BR0107751A (en)
CA (1) CA2397961C (en)
CO (1) CO5261549A1 (en)
CR (1) CR6706A (en)
CZ (1) CZ20022475A3 (en)
DZ (1) DZ3266A1 (en)
EA (1) EA200200643A1 (en)
EE (1) EE200200405A (en)
GT (1) GT200100016A (en)
HN (1) HN2001000013A (en)
HU (1) HUP0204141A3 (en)
IL (1) IL150545A0 (en)
IS (1) IS6443A (en)
MA (1) MA26868A1 (en)
MX (1) MXPA02007221A (en)
NO (1) NO20023527L (en)
OA (1) OA12161A (en)
PA (1) PA8510701A1 (en)
PE (1) PE20011066A1 (en)
PL (1) PL356802A1 (en)
SK (1) SK10632002A3 (en)
SV (1) SV2002000294A (en)
TN (1) TNSN01014A1 (en)
WO (1) WO2001055147A1 (en)
YU (1) YU50402A (en)
ZA (1) ZA200205879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2426654C (en) 2000-10-23 2010-12-21 Smithkline Beecham Corporation 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
PE20030008A1 (en) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
CN1646131A (en) 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 Novel compounds
EA200500721A1 (en) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Pyrimidines inhibiting CHK, PDK and ACT, THEIR RECEIVING AND USING AS MEDICINES
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
CN101014600A (en) * 2004-09-21 2007-08-08 霍夫曼-拉罗奇有限公司 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
PE20061351A1 (en) 2005-03-25 2007-01-14 Glaxo Group Ltd 8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
PE20100741A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
MX2007012951A (en) 2005-03-25 2008-01-11 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives.
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
ATE449097T1 (en) * 2005-07-21 2009-12-15 Hoffmann La Roche PYRIDOÄ2,3-DÜPYRIMIDINE-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORS
CA2617359A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
FR2910813B1 (en) * 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CN102216299B (en) * 2008-12-01 2015-02-11 默克专利有限公司 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014151682A1 (en) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (en) * 2014-09-02 2016-11-02 한국원자력의학원 Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof
CN107286180B (en) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 Miscellaneous generation Pyridopyrimidinone derivatives are as CDK inhibitor and its application
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20012444B (en) * 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
YU73300A (en) * 1998-05-26 2003-08-29 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydro-pyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
AU2542501A (en) 2001-08-07
NO20023527L (en) 2002-09-10
CN1395578A (en) 2003-02-05
WO2001055147A1 (en) 2001-08-02
BG106850A (en) 2003-02-28
NO20023527D0 (en) 2002-07-24
CA2397961C (en) 2008-08-26
SK10632002A3 (en) 2003-06-03
OA12161A (en) 2006-05-08
PA8510701A1 (en) 2002-12-11
BR0107751A (en) 2002-11-12
IL150545A0 (en) 2003-02-12
GT200100016A (en) 2001-10-19
ZA200205879B (en) 2003-09-29
AP2002002586A0 (en) 2002-09-30
JP4047010B2 (en) 2008-02-13
IS6443A (en) 2002-06-25
PL356802A1 (en) 2004-07-12
SV2002000294A (en) 2002-07-16
HUP0204141A3 (en) 2005-03-29
CZ20022475A3 (en) 2003-03-12
CA2397961A1 (en) 2001-08-02
MXPA02007221A (en) 2002-11-29
MA26868A1 (en) 2004-12-20
EP1254137A1 (en) 2002-11-06
EE200200405A (en) 2003-12-15
AR030044A1 (en) 2003-08-13
HUP0204141A2 (en) 2003-04-28
CO5261549A1 (en) 2003-03-31
CR6706A (en) 2005-04-04
TNSN01014A1 (en) 2005-11-10
DZ3266A1 (en) 2001-08-02
JP2003523357A (en) 2003-08-05
KR20020065939A (en) 2002-08-14
HN2001000013A (en) 2001-06-18
YU50402A (en) 2005-11-28
PE20011066A1 (en) 2001-10-22

Similar Documents

Publication Publication Date Title
EA200200643A1 (en) PYRIDO [2,3-d] PYRIMIDIN-2,7-DIAMINE KINAZ INHIBITORS
EA200701991A1 (en) NEW IMIDAZO DERIVATIVES [1,5-a] PYRIDINES, METHOD OF THEIR RECEPTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EA200200802A1 (en) 5-ALKYLPYRIDO [2.3-d] Pyrimidine Thyrosine Kinase Inhibitors
IL256375A (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201891463A1 (en) PYRAZOLO [1,5-a] PYRAZIN-4-ILA DERIVATIVES AS JANUS KINASE INHIBITORS (JAK)
ATE503483T1 (en) ACT ACTIVITY INHIBITOR
EA200000188A1 (en) DERIVATIVES 2,3-DIARYL-PYRAZOLO [1,5-B] -PYRIDAZINES, THEIR RECEIVING AND THEIR APPLICATION AS CYCLOXYGENASE-2 INHIBITORS (COX-2)
NO20082101L (en) Pyrido, pyrazo and pyrimido-pyrimidine derivatives as mTor inhibitors
WO1999061444A3 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
WO2004096130A3 (en) Inhibitors of akt activity
RU2003122190A (en) TETRAHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND APPLICATION AS CELL PROLIFERATION INHIBITORS
HUP9801177A2 (en) Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them
EA200600973A1 (en) PYRIDO [2,3-d] PYRIMIDIN-2,4-DIAMINS AS PDE 2 INHIBITORS
PE20020976A1 (en) PIRIDO-PYRIMIDINES 6-SUBSTITUTED AS KINASE INHIBITORS
TR200401903T4 (en) Imidazole-2-carboxamide derivatives as shelf kinase inhibitor.
HRP20030791B1 (en) DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGluR2 ANTAGONISTS I
KR880009019A (en) Tricyclic Benzimidazoles, Methods for Making the Same, and Pharmacological Compositions Containing Them
EP1799689A1 (en) Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents
NZ599553A (en) Ethynyl derivatives
DE60214401D1 (en) HETERO BICYCLIC CRF ANTAGONISTS
AU6785201A (en) Novel pyrazinone derivatives
FI964463A0 (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
RU2149000C1 (en) Use of carbocyclic and heterocyclic anellated dihydropyridines and their pharmaceutically acceptable salts as blocker of nonselective channel of cations in protection of brain and for treatment of patients with chronic bronchial asthma
HUP0302753A2 (en) Urea and urethane derivatives as integrin inhibitors, process for their preparation, their use and pharmaceutical compositions containing them
EA200100816A1 (en) 2-AMINOPYRIDINES CONTAINING CONDENSED RINGS AS DEPUTIES